LL-37
cathelicidinhcap-18
Cathelicidin antimicrobial peptide. Limited human data; framework focuses on infection and inflammation markers.
- Half-life
- Not established
- Out of system
- —
- Route
- Subcutaneous
- Level
- Intermediate
What LL-37 is used for
- Cathelicidin antimicrobial peptide — innate-immune research
- Studied for infection and chronic inflammation
How it's typically used
Research range: ~0.1 mg subcutaneous daily, short courses.
What to watch for
- Can be pro-inflammatory at higher doses — biphasic effects
- Very limited human safety data
- Not FDA-approved; injection-site reactions reported
About Healing & recovery
- What they are
- Repair peptides — short amino-acid chains studied for soft-tissue, tendon, and gut-lining healing. Almost all the evidence is animal or preclinical; human trials are scarce.
- How they're run
- Reconstituted from a lyophilised (freeze-dried) powder and injected subcutaneously, usually daily, in blocks of 4–6 weeks around a specific injury.
- What to watch
- None are approved drugs, so purity depends entirely on the source. Effects are gradual — judge a block by whether the injury measurably improved, not by how you feel on day 3.
Full guide
LL-37: A Tracking Guide for the Cathelicidin Peptide
How to log LL-37 use across antimicrobial and inflammation endpoints, with honest notes on the limited human data.
Other healing & recovery
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.